Two of Opus's seven gene therapy assets are in clinical trials, with additional programs expected to enter the clinic.

Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

We built TheraTrack to make therapy feel even clearer and more supportive. With simple visual tools, clients and clinicians can stay aligned and make informed decisions together throughout care.” — ...

Researchers have explored potential treatment that could bring unexpected relief to people living with severe vision loss.The ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Screens steal our focus all day, leaving eyes gritty and slow to shift, but four simple exercises can revive smooth movement ...

In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Idaho families face new Medicaid therapy caps and fear worse is coming after Gov. Little proposed eliminating speech, ...

AI diagnostics, wearable health monitors, and digital health devices showcased at CES 2026 signal a major shift toward ...

The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...